On or around 10/04/2019 (Date of last review)
Filing Date: February 22, 2019
According to the Complaint, Amarin is a biotechnology company with its headquarters located in Dublin, Ireland.
The Complaint alleges that during the Class Period, Defendants made false and misleading statements or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times.
On May 14, 2019, the Court issued an Order appointing Co-Lead Plaintiffs and Counsel. Lead Plaintiffs filed an amended Complaint on July 22.
Company & Securities Information
Defendant: Amarin Corporation plc
Industry: Biotechnology & Drugs
Ticker Symbol: AMRN
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Debendra Sharma, et al. v. Amarin Corporation plc, et al.